Physician profile
Ganana Tesfa
NPI 1891844577
$13,102.00
in general payments reported to CMS, 2019-2025
57 companies · $2,105 in 2025
The $2,105 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $1,555 · 2021: $2,266 · 2022: $2,112 · 2023: $1,942 · 2024: $1,990 · 2025: $2,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,036 · Education: $1.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,035.82 |
| Education | $1.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,525.38 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Supernus Pharmaceuticals, INC. | $810.28 | 2019-2025 | Qelbree |
| Ucb, INC. | $770.52 | 2019-2025 | Briviact, Rystiggo |
| Sk Life Science, INC. | $703.68 | 2020-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $656.07 | 2020-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Pfizer INC. | $649.85 | 2020-2025 | |
| Lilly USA, LLC | $547.72 | 2020-2025 | Emgality, Reyvow |
| Biogen, INC. | $521.50 | 2019-2025 | Tysabri, Vumerity |
| Sunovion Pharmaceuticals INC. | $396.55 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $377.30 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $374.18 | 2021-2025 | Rytary, Crexont, Brekiya |
| Emd Serono, INC. | $373.68 | 2019-2022 | |
| Amgen INC. | $333.80 | 2020-2025 | Uplizna, Aimovig |
| Otsuka America Pharmaceutical, INC. | $307.42 | 2023-2025 | Nuedexta, Rexulti |
| Allergan, INC. | $298.08 | 2019-2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ganana Tesfa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.